Limits...
Controlled Delivery of Human Cells by Temperature Responsive Microcapsules.

Mak WC, Olesen K, Sivlér P, Lee CJ, Moreno-Jimenez I, Edin J, Courtman D, Skog M, Griffith M - J Funct Biomater (2015)

Bottom Line: However, its full potential is limited by the rapid loss of introduced therapeutic cells before their full effects can be exploited, due in part to anoikis, and in part to the adverse environments often found within the pathologic tissues that the cells have been grafted into.Cell encapsulation and controlled release was demonstrated using human fibroblasts as model cells, as well as a therapeutically relevant cell line-human umbilical vein endothelial cells (HUVECs).While such temperature responsive cell microcapsules promise effective, controlled release of potential therapeutic cells at physiological temperatures, further work will be needed to augment the composition of the microcapsules and optimize the numbers of cells per capsule prior to clinical evaluation.

View Article: PubMed Central - PubMed

Affiliation: Integrative Regenerative Medicine Centre, Department of Clinical and Experimental Medicine, Linköping University, SE58185, Linköping, Sweden. mamak@ifm.liu.se.

ABSTRACT
Cell therapy is one of the most promising areas within regenerative medicine. However, its full potential is limited by the rapid loss of introduced therapeutic cells before their full effects can be exploited, due in part to anoikis, and in part to the adverse environments often found within the pathologic tissues that the cells have been grafted into. Encapsulation of individual cells has been proposed as a means of increasing cell viability. In this study, we developed a facile, high throughput method for creating temperature responsive microcapsules comprising agarose, gelatin and fibrinogen for delivery and subsequent controlled release of cells. We verified the hypothesis that composite capsules combining agarose and gelatin, which possess different phase transition temperatures from solid to liquid, facilitated the destabilization of the capsules for cell release. Cell encapsulation and controlled release was demonstrated using human fibroblasts as model cells, as well as a therapeutically relevant cell line-human umbilical vein endothelial cells (HUVECs). While such temperature responsive cell microcapsules promise effective, controlled release of potential therapeutic cells at physiological temperatures, further work will be needed to augment the composition of the microcapsules and optimize the numbers of cells per capsule prior to clinical evaluation.

No MeSH data available.


Related in: MedlinePlus

Kinetics of cell release from temperature responsive microcapsules comprising 1% low melting agarose, 0.1% to 0.5% gelatin, and 10 mg·mL−1 fibrinogen, showing that 28% of cells were released within 24 h, and 70% cells were released by 48 h.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4493523&req=5

jfb-06-00439-f006: Kinetics of cell release from temperature responsive microcapsules comprising 1% low melting agarose, 0.1% to 0.5% gelatin, and 10 mg·mL−1 fibrinogen, showing that 28% of cells were released within 24 h, and 70% cells were released by 48 h.

Mentions: The kinetics of cell delivery defined by the percentage of encapsulated cell delivered/released from hydrogel capsules was measured by counting the initial number of encapsulated cells (inside hydrogel capsule with rounded morphology) and released cells as a function of time. For microcapsules comprising 1% low melting agarose, 0.5% gelatin, and 10 mg mL−1 fibrinogen, 28% of the cells were released within 24 h of incubation at 37 °C. By 48 h, 70% of cells were released (Figure 6).


Controlled Delivery of Human Cells by Temperature Responsive Microcapsules.

Mak WC, Olesen K, Sivlér P, Lee CJ, Moreno-Jimenez I, Edin J, Courtman D, Skog M, Griffith M - J Funct Biomater (2015)

Kinetics of cell release from temperature responsive microcapsules comprising 1% low melting agarose, 0.1% to 0.5% gelatin, and 10 mg·mL−1 fibrinogen, showing that 28% of cells were released within 24 h, and 70% cells were released by 48 h.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4493523&req=5

jfb-06-00439-f006: Kinetics of cell release from temperature responsive microcapsules comprising 1% low melting agarose, 0.1% to 0.5% gelatin, and 10 mg·mL−1 fibrinogen, showing that 28% of cells were released within 24 h, and 70% cells were released by 48 h.
Mentions: The kinetics of cell delivery defined by the percentage of encapsulated cell delivered/released from hydrogel capsules was measured by counting the initial number of encapsulated cells (inside hydrogel capsule with rounded morphology) and released cells as a function of time. For microcapsules comprising 1% low melting agarose, 0.5% gelatin, and 10 mg mL−1 fibrinogen, 28% of the cells were released within 24 h of incubation at 37 °C. By 48 h, 70% of cells were released (Figure 6).

Bottom Line: However, its full potential is limited by the rapid loss of introduced therapeutic cells before their full effects can be exploited, due in part to anoikis, and in part to the adverse environments often found within the pathologic tissues that the cells have been grafted into.Cell encapsulation and controlled release was demonstrated using human fibroblasts as model cells, as well as a therapeutically relevant cell line-human umbilical vein endothelial cells (HUVECs).While such temperature responsive cell microcapsules promise effective, controlled release of potential therapeutic cells at physiological temperatures, further work will be needed to augment the composition of the microcapsules and optimize the numbers of cells per capsule prior to clinical evaluation.

View Article: PubMed Central - PubMed

Affiliation: Integrative Regenerative Medicine Centre, Department of Clinical and Experimental Medicine, Linköping University, SE58185, Linköping, Sweden. mamak@ifm.liu.se.

ABSTRACT
Cell therapy is one of the most promising areas within regenerative medicine. However, its full potential is limited by the rapid loss of introduced therapeutic cells before their full effects can be exploited, due in part to anoikis, and in part to the adverse environments often found within the pathologic tissues that the cells have been grafted into. Encapsulation of individual cells has been proposed as a means of increasing cell viability. In this study, we developed a facile, high throughput method for creating temperature responsive microcapsules comprising agarose, gelatin and fibrinogen for delivery and subsequent controlled release of cells. We verified the hypothesis that composite capsules combining agarose and gelatin, which possess different phase transition temperatures from solid to liquid, facilitated the destabilization of the capsules for cell release. Cell encapsulation and controlled release was demonstrated using human fibroblasts as model cells, as well as a therapeutically relevant cell line-human umbilical vein endothelial cells (HUVECs). While such temperature responsive cell microcapsules promise effective, controlled release of potential therapeutic cells at physiological temperatures, further work will be needed to augment the composition of the microcapsules and optimize the numbers of cells per capsule prior to clinical evaluation.

No MeSH data available.


Related in: MedlinePlus